ArticleScientific reports2025
Rinsenoside Rg1 and its involvement in Hippo-YAP signaling pathway alleviating symptoms of depressive-like behavior.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Sex-Specific Hippocampal Phosphoproteomic Features Associated with Stress-Induced Phenotypes in Mice Exposed to Chronic Restraint Stress.Neurochemical research · 2026Article
- Ginsenosides in the management of depression: a comprehensive pharmacological review.Chinese medicine · 2026Review
- Ginsenoside Rg1 ameliorates lipopolysaccharide-induced depressive-like behaviors in mice by attenuating neuroinflammation and neuronal damage.Scientific reports · 2026Article
- The Role of miRNAs in the Differential Diagnosis of Alzheimer's Disease and Major Depression: A Bioinformatics-Based Approach.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Ginsenoside Rg1 (G-Rg1) has potential antidepressant effects, but the underlying mechanism remains unclear. Presently, sixty 6-8 week-old male C57BL/6 mice were selected and randomly allocated to control, chronic restraint stress (CRS), CRS and low G-Rg1 administration (CRS + L-Rg1), CRS and high G-Rg1 administration (CRS + H-Rg1), and CRS and fluoxetine administration (CRS + FLX) groups. The component of anxiety in psychic processes and neuropathological changes occurring in dentate gyrus (DG) neurons were evaluated, where PC12 cells were assessed for the expression of G-Rg1. Both cell viability and apoptosis were analyzed. G-Rg1 (5 and 10 mg/kg/day) alleviated the behavioral manifestations of neuropathological processes revealed in DG neurons of CRS-induced mice. Western blotting analysis demonstrated the negative correlation of G-Rg1 level and that of Hipp-YAP signaling pathway components including p-YAP/YAP, p-MST1/MST1, and p-LATS1/LATS1, which were triggered by CRS. Combined therapy with G-Rg1 (10 mM) proved to have an inhibitory effect on PC12 cell viability and apoptosis compared to sole cort treatment. In addition, chronic G-Rg1 also reduced the protein expression levels of Hippo-YAP signaling pathway activated by corticosterone (Cort) including p-YAP/YAP, p-MST1/MST1, and p-LATS1/LATS1. The above mentioned improvements could be implemented due to XMU-MP-1 hampering the processes in Hippo-YAP signaling pathway. Importantly, the changes in synaptic plasticity and apoptosis were thoroughly investigated to determine the role of chronic G-Rg1 in the forementioned processes. In conclusion, chronic G-Rg1 played an important neuroprotective role in either CRS mice or Cort-treated cells associated with the inhibition of Hippo-YAP signaling pathway, which was the core part of decreasing neuronal apoptosis and enhancing synaptic plasticity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.